Arca
Skip to content
Tools
Tools

SLC5A1: Sodium/glucose cotransporter 1

Electrogenic Na(+)-coupled sugar symporter that actively transports D-glucose or D-galactose at the plasma membrane, with a Na(+) to sugar coupling ratio of 2:1.

  • Drugs that act on it: 2
  • Approved: 1
  • In phases 1 to 3: 1
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on SLC5A1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 2

Approved1

  • Sotagliflozin

Phase 30

    Phase 21

    • Licogliflozin

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      SotagliflozinApprovedLexicon PharmaceuticalsSmall moleculeInhibitorSodium/glucose cotransporter 1 inhibitor19
      LicogliflozinPhase 2Novartis PharmaceuticalsSmall moleculeInhibitorSodium/glucose cotransporter 1 inhibitor0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
      Cardiovascular and Renal Protection With SGLT Inhibition in Kidney Transplant Recipients: The RENAISSANCE TrialSotagliflozinPhase 3Not yet recruitingUniversity of British ColumbiaNov 18, 2026
      Sotagliflozin to Lower Proteinuria in Recipients of a Kidney TransplantSotagliflozinPhase 3Not yet recruitingFinnian Mc CauslandNov 17, 2026
      Sotagliflozin Versus Empagliflozin Added to Metformin for Glycemic Control in Type 2 DiabetesSotagliflozinPhase 4Not yet recruitingAllied Hospital FaisalabadNov 16, 2026
      Precision T1D Platform - New Therapies for Cardio-Renal ComplicationsSotagliflozinPhase 2Not yet recruitingOregon Health and Science UniversityMay 18, 2026
      Sotagliflozin as Prevention of Anthracycline-Related CardiotoxicitySotagliflozinPhase 2Not yet recruitingIcahn School of Medicine at Mount SinaiMay 7, 2026
      Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)SotagliflozinPhase 4Enrolling by invitationBaylor Research InstituteApr 23, 2026
      Ketone Monitoring Approaches for Diabetic Ketoacidosis Risk Mitigation in People With T1D on Adjunctive SGLT-2 InhibitorsSotagliflozinPhase 2Not yet recruitingAdventHealth Translational Research InstituteFeb 19, 2026
      Mitigating DKA in Type 1 Diabetes for Safe Use of SGLT Inhibitors Using Dual Continuous Ketone and Glucose Monitoring.SotagliflozinPhase 2Not yet recruitingHealthPartners InstituteJan 8, 2026

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      • Glucose-galactose malabsorption0.82
      • Type 2 diabetes mellitus0.54
      • Type 1 diabetes mellitus0.51
      • Abnormal glucose tolerance0.37
      • Nasopharyngeal neoplasm0.37
      • Renal glycosuria0.27
      • Cardiovascular disorder0.26

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4979, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P13866, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.